Glioblastoma (GBM): Symptoms, Diagnosis, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Glioblastoma (GBM) is a WHO Grade 4 astrocytoma and the most aggressive primary brain tumor in adults, accounting for approximately 48% of all primary malignant brain tumors. Approximately 15,000 new US cases are diagnosed annually. Median age at diagnosis is 64 years. IDH-wildtype GBM (primary, approximately 90%) occurs in older adults de novo; IDH-mutant GBM (secondary, approximately 10%) arises from lower-grade glioma progression in younger patients and has a better prognosis. Glioblastoma (GBM): Symptoms, Diagnosis, and Treatment is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Glioblastoma (GBM): Symptoms, Diagnosis, and Treatment to help patients understand the condition, its causes, symptoms, and available treatment options.

IDH-wildtype GBM is characterized by TERT promoter mutation (approximately 80%), EGFR amplification (approximately 50%), CDKN2A/B homozygous deletion, and chromosome 7 gain with chromosome 10 loss. Ionizing radiation to the head (therapeutic) is the only confirmed environmental risk factor. Hereditary syndromes including Li-Fraumeni syndrome (TP53 germline), Lynch syndrome, and neurofibromatosis type 1 confer elevated risk. No confirmed link to mobile phone use. IDH-mutant GBM shows prior lower-grade glioma progression with IDH1/2 mutation, ATRX loss, and CDKN2A/B homozygous deletion. The causes of Glioblastoma (GBM): Symptoms, Diagnosis, and Treatment are often multifactorial, involving a combination of genetic predisposition, environmental exposures, and lifestyle factors. In some cases, infectious agents, immune dysfunction, or metabolic imbalances may contribute. Risk factors vary but may include age, sex, family history, and pre-existing medical conditions. Understanding the causes guides prevention strategies and informs treatment choices.

GBM presents with rapidly progressive neurological symptoms over weeks to months. Headache (often worse in the morning and with position change), seizures (in approximately 30%), focal neurological deficits (motor weakness, aphasia, visual changes depending on tumor location), personality and cognitive changes, and nausea or vomiting from raised intracranial pressure are common. Confusion, drowsiness, and herniation signs indicate severe ICP elevation. Symptoms typically worsen rapidly due to the aggressive growth pattern of GBM. Symptoms of Glioblastoma (GBM): Symptoms, Diagnosis, and Treatment can range from mild to severe and may develop gradually or appear suddenly. Common presentations include pain, inflammation, or functional impairment related to the affected system. Symptoms may fluctuate over time with periods of remission and exacerbation. Consult a healthcare provider if symptoms persist or worsen, as early diagnosis improves outcomes.

MRI with gadolinium is the diagnostic imaging standard: GBM appears as a heterogeneous mass with irregular ring-enhancing margins, central necrosis, and surrounding T2/FLAIR signal edema. Spectroscopy shows elevated choline and reduced NAA. Surgical resection or biopsy provides tissue for WHO 2021 molecular classification: IDH status, TERT promoter, EGFR amplification, chromosome 7 gain/10 loss, MGMT promoter methylation status, H3 K27 and G34 mutations, and CDKN2A/B homozygous deletion. Full neuraxis staging is not routinely required. Diagnosis of Glioblastoma (GBM): Symptoms, Diagnosis, and Treatment typically involves a thorough clinical history, physical examination, and targeted investigations. Laboratory tests, imaging studies, or specialist referrals may be required to confirm the diagnosis. Accurate diagnosis is essential for appropriate management and prevents unnecessary treatment.

Standard treatment (Stupp protocol) for eligible patients: maximal safe surgical resection followed by concurrent temozolomide (75 mg/m2 daily) plus 60Gy radiotherapy in 30 fractions, then 6 cycles of adjuvant temozolomide (150-200 mg/m2). TTFields (Optune) worn greater than or equal to 18 hours per day added to maintenance TMZ improves median OS to 20.9 months (EF-14 trial). Elderly or poor performance status patients: hypofractionated radiation (40Gy in 15 fractions) plus temozolomide (MGMT-methylated) or radiation alone. Bevacizumab for recurrent GBM (improves PFS, not OS). Clinical trials with immunotherapy (nivolumab, pembrolizumab, CAR-T, vaccines) are actively enrolling. Treatment of Glioblastoma (GBM): Symptoms, Diagnosis, and Treatment is tailored to the individual and depends on severity and underlying cause. Options may include medications, lifestyle modifications, surgical interventions, or supportive therapies. Multidisciplinary care is often recommended for complex cases. The goal is to alleviate symptoms, slow disease progression, and improve quality of life.

GBM has the poorest prognosis of all glioma subtypes. Median OS with Stupp protocol is approximately 14.6 months; with TTFields added, approximately 20.9 months. Two-year OS is approximately 30% with combined Stupp plus TTFields. Five-year survival is less than 10% for IDH-wildtype GBM. MGMT-methylated GBM has median OS of 21-23 months versus 12-15 months for unmethylated. IDH-mutant grade 4 astrocytoma has a significantly better median OS of 24-31 months. Age, performance status, extent of resection, and MGMT methylation are the strongest independent prognostic factors. The prognosis for Glioblastoma (GBM): Symptoms, Diagnosis, and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

No established environmental risk factors permit preventive strategies for sporadic GBM. Unnecessary cranial irradiation should be avoided, particularly in children. Patients with hereditary predisposition syndromes (Li-Fraumeni, Lynch syndrome) should undergo annual brain MRI surveillance. Research into GBM immunoprevention (vaccines targeting neoantigens) is in early stages. Population-based screening for GBM is not currently recommended due to lack of effective early detection biomarkers. Genetic counseling is warranted for patients with GBM under age 45. Prevention strategies for Glioblastoma (GBM): Symptoms, Diagnosis, and Treatment focus on reducing modifiable risk factors and promoting overall health. Lifestyle interventions such as a balanced diet, regular physical activity, and avoidance of tobacco and excessive alcohol are beneficial. Routine screening and early detection are important where treatment is more effective at early stages.

Call emergency services immediately for new-onset seizure, sudden severe headache, acute focal neurological deficit (arm or leg weakness, speech loss, visual loss), or decreasing level of consciousness — these are neurological emergencies that can indicate GBM or herniation. See a neurologist urgently within 1-2 weeks for progressive headache worsening over days to weeks (especially worse in the morning or on lying flat), gradual focal weakness, speech or language difficulty, persistent personality change, cognitive decline, or visual disturbances of new onset. Patients with hereditary syndromes (Li-Fraumeni syndrome, Lynch syndrome) should undergo annual brain MRI surveillance. Prior cranial irradiation patients require periodic MRI given elevated secondary glioma risk.